Top Investments Named for the 2022 Year by New Zealand Private Capital Association
The New Zealand Private Capital Association unveiled this year’s winners of its prestigious investments of the year awards at its annual conference in Queenstown yesterday (20 October).
NZ Private Capital ANNUAL AWARD WINNERS:
VENTURE INVESTMENT OF THE YEAR
Awarded to Movac for their investment in Aroa Biosurgery.
INVESTMENT OF THE YEAR up to $300 million
Awarded to Waterman Private Capital for their investment in Canopy Healthcare Group.
INVESTMENT OF THE YEAR over $300 million
Awarded to Next Capital for their investment in NZ Bus.
Commenting on the awards NZ Private Capital Executive Director, Colin McKinnon says: “The quality and sophistication of firms involved in investment in New Zealand and the value that is being added to local businesses just keeps on getting better.
“The winners of our 2022 awards are examples of private capital partnering with companies to improve growth and performance, and to share expertise and to provide capital. This ultimately delivers improved productivity, creates jobs and contributes to the national economy.”
Entries were judged on return to investors and the companies’ financial performance. The companies’ contributions to the economy, employment, innovation, resilience and industry competitiveness were also considered.
Mr McKinnon adds: “The NZ Private Capital Investment of Year Awards recognise the private equity and venture capital firms that accelerate the ambition of New Zealand business owners through operational improvement and investment performance.”
Further information:
Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction. Aroa’s primary market is the USA, with revenue driven by USA-based sales. The use cases for Aroa products are in human surgical and non-surgical wound healing. The products are sold through multiple channels to hospital-based care providers, outpatient care providers, as well as direct to consumers. Aroa is headquartered in Auckland, where all Research and Development (R&D) and manufacturing takes place. The manufacturing facilities were recently expanded, adding additional high-value manufacturing capability and capacity in New Zealand. The business continues to invest heavily in R&D, with multiple new products and use cases in the development pipeline.
Movac is one of New Zealand’s most experienced and successful venture investors, proudly partnering with Kiwi entrepreneurs to accelerate and grow their businesses – for the benefit of all New Zealanders.
Canopy Healthcare Group created a multi-service platform delivering benefits for patients, referrers, funders and staff. The approximate doubling of workforce over the investment period established over 100 new jobs, including 40 in rural geographic centres. The company expanded the Group’s footprint, including private medical oncology clinics in regions that had previously had no provider – in some cases reducing patient travelling times by over five hours. The group invested in multiple high tech diagnostic imaging machines, simultaneously improving efficiency and patient outcomes.
Waterman Private Capital has a long history of investing in and adding value to businesses in the mid-market space. These companies form the heart of the New Zealand economy and offer significant growth potential. Waterman is an active investor and sees its success being driven by a philosophy of working collaboratively with management teams, other shareholders and stakeholders.
NZ Bus achieved a range of critical ESG outcomes across decarbonisation, environmental outcomes and driver pay, conditions and safety while undergoing a business transformation resulted in sustainable earnings growth. The company reinvigorating the businesswith a renewed focus on collaborative council relationships and operational excellence. NZ Bus achieved a broad suite of market leading ESG outcomes including fleet electrification driving decarbonisation. NZ Bus led the market in accelerating electric vehicle (EV) deployment, exemplified by Australasia’s largest order of EVs (152 in a single order in Auckland representing approximately NZ$140 million capital expenditure).
The Next Capital team has a strong operational focus, based on cultivating successful partnerships with investee company founders and management over many years. The Next Capital team have a strong track record of working with management to generate returns for vendors, management and investors alike. With over $600 million of funds under management and substantial capital available for new investment, the Next Capital team dedicate the resources necessary to work through opportunities in a timely and professional manner.
ENDS
Contact:
Colin McKinnon, Executive Director,
New Zealand Private Capital Association, New Zealand
+64 27 640 6406